869587-03-1Relevant academic research and scientific papers
Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors
Xu, Jinyou,Wei, Lan,Mathvink, Robert J.,Edmondson, Scott D.,Eiermann, George J.,He, Huaibing,Leone, Joseph F.,Leiting, Barbara,Lyons, Kathryn A.,Marsilio, Frank,Patel, Reshma A.,Patel, Sangita B.,Petrov, Aleksandr,Scapin, Giovanna,Wu, Joseph K.,Thornberry, Nancy A.,Weber, Ann E.
, p. 5373 - 5377 (2006)
A novel series of oxadiazole based amides have been shown to be potent DPP-4 inhibitors. The optimized compound 43 exhibited excellent selectivity over a variety of DPP-4 homologs.
1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
-
Page/Page column 46-47, (2010/02/14)
The present invention is directed to novel 1,2,4-oxadiazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
